To evaluate the effects of aCT1 in this context, we performed a cell-coupling assay (Figure 1A) using the JIMT-1 cell line, which is a HER2+ breast cancer cell line that was isolated from a patient that had developed resistance to trastuzumab (aka Herceptin) [48]. Here, ERBB2 is linked to breast carcinoma.